Skip to main content
. 2021 Nov 12;6(6):100300. doi: 10.1016/j.esmoop.2021.100300

Table 2.

Reproductive outcomes after breast cancer treatment

Reproductive outcomes ART group (n = 22) Non-ART group (n = 146)
Median age at the time of pregnancy, years (IQR) 39.7 (35.3-41.4) 35.4 (32.7-38.0)
Median time from breast cancer diagnosis to conception, years (IQR) 5.4 (2.4-6.7) 3.5 (2.3-5.2)
Pregnancy outcomes, n (%)
 Live birth 18 (81.8) 113 (77.4)
 Ongoing 1 (4.6) 4 (2.7)
 Induced abortion 0 (0.0) 13 (8.9)
 Miscarriage 3 (13.6) 15 (10.3)
 Unknown 0 (0.0) 1 (0.7)
Timing of delivery, n (%)
 At term (≥37 weeks) 11 (61.1) 84 (74.3)
 Preterm (<37 weeks) 3 (16.7) 7 (6.2)
 Unknown 4 (22.2) 22 (19.5)
Pregnancy complications, n (%)
 None 10 (45.5) 82 (56.2)
 Delivery complications 5 (22.7) 6 (4.1)
 Congenital abnormalities 1 (4.5) 3 (2.0)
 No. missing 6 (27.3) 55 (37.7)
Breast feeding, n (%)
 Yes 2 (9.1) 28 (19.2)
 No 8 (36.4) 43 (29.4)
 Unknown 12 (54.5) 75 (51.4)
 Median duration (years) 0 1
Type of ART, n (%) Not applicable
 Embryo transfer under HRT following oocyte and/or embryo cryopreservation at diagnosis 4 (18.2)
 Embryo transfer under HRT following oocyte donation 5 (22.7)
 Ovarian stimulation for IVF/ICSI after cancer treatment 7 (31.8)
 Ovulation induction 1 (4.5)
 Unknown 5 (22.7)

ART, assisted reproductive technologies; HRT, hormonal replace therapy; ICSI, intracytoplasmic sperm injection; IQR, interquartile range; IVF, in vitro fertilization.